# Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

> **NCT04187898** · PHASE1 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 59 (actual)

## Conditions studied

- Neutropenia
- Breast Cancer

## Interventions

- **BIOLOGICAL:** Eflapegrastim
- **BIOLOGICAL:** Eflapegrastim
- **BIOLOGICAL:** Eflapegrastim
- **BIOLOGICAL:** Eflapegrastim
- **DRUG:** Docetaxel
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04187898
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-11
- **Primary completion:** 2024-07-16
- **Final completion:** 2024-08-16
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04187898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04187898, "Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04187898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*